• 8347 Citations
20002021

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research Interests

Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Clinical trials

Training Experience

1995Internship, Mount Sinai Hospital, New York
1996Residency, Mount Sinai Hospital, New York

Education/Academic qualification

MD, University of Rome La Sapienza

… → 1988

Research interests

  • Blood Cancer (leukemia and lymphomas)
  • Clinical Research

Fingerprint Dive into the research topics where Barbara Pro is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 15 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants

Research Output

Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry

Lansigan, F., Horwitz, S. M., Pinter-Brown, L. C., Rosen, S. T., Pro, B., Hsi, E. D., Federico, M., Gisselbrecht, C., Schwartz, M., Bellm, L. A., Acosta, M., Shustov, A. R., Advani, R. H., Feldman, T., Lechowicz, M. J., Smith, S. M., Tulpule, A., Craig, M. D., Greer, J. P., Kahl, B. S. & 5 others, Leach, J. W., Morganstein, N., Casulo, C., Park, S. I. & Foss, F. M., Jan 1 2020, In : Acta Haematologica. 143, 1, p. 40-50 11 p.

Research output: Contribution to journalArticle

  • 1 Scopus citations

    Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    ECHELON-2 Study Group, Jan 19 2019, In : The Lancet. 393, 10168, p. 229-240 12 p.

    Research output: Contribution to journalArticle

  • 64 Scopus citations

    Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma

    Khashab, T., Hagemeister, F., Romaguera, J. E., Fanale, M. A., Pro, B., McLaughlin, P., Rodriguez, M. A., Neelapu, S. S., Fayad, L., Younes, A., Feng, L., Vega, F., Kwak, L. W. & Samaniego, F., May 2019, In : British Journal of Haematology. 185, 4, p. 670-678 9 p.

    Research output: Contribution to journalArticle

  • Novel therapies and approaches to relapsed/refractory HL beyond chemotherapy

    Mina, A. A., Vakkalagadda, C. & Pro, B., Mar 2019, In : Cancers. 11, 3, 421.

    Research output: Contribution to journalReview article

    Open Access
  • 1 Scopus citations

    Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry

    Stuver, R. N., Khan, N., Schwartz, M., Acosta, M., Federico, M., Gisselbrecht, C., Horwitz, S. M., Lansigan, F., Pinter-Brown, L. C., Pro, B., Shustov, A. R., Foss, F. M. & Jain, S., Jun 2019, In : American Journal of Hematology. 94, 6, p. 641-649 9 p.

    Research output: Contribution to journalArticle

  • 2 Scopus citations